Ziccum - Vd-intervju

(8:15)

Ziccum - vd intervju Q3 2024

(13:46)

Ziccum - vd intervju Q2 2024

(16:1econd)

Ziccum - CEO comment on the most recent Evaluation Agreement

(9:47)

Ziccum | BioStock Life Science Summit 2024

(14:56)

Ziccum CEO Analyst video interview: Q1, 2024

(10:)

Ziccum: Air-drying biologics: and vaccines

(3:43)

Ziccum vd-intervju: mRNA i fokus / fördjupning

(16:47)

Ziccum | INTERVIEW | Investing in Life Science 2024

(5:15)

Ziccum | VD Ann Gidner \

(6:16)

ZICCUM: Safe delivery in all climates

(2:29)

Thermostable vaccines at volume: How Ziccum plans to scale up its production of dry-powder vaccines

(3:31)

BioStock Life Science Fall Summit 2022 | Presentation: Ziccum

(16:44)

Ziccum | Investing in Life Science 2024

(14:57)

Eucaps Talks - Interview with Ziccum´s CEO, Ann Gidner

(12:7)

Set Vaccines Free: How ambient air-drying can create thermostable vaccines that need no Cold Chain.

(5:28)

How does Ziccum formulate vaccines as dry powders? Meet Ziccum Project Manager Louise Egeblad

(3:51)

Ziccum - CEO Report Commentary Q2-2023

(9:14)

Panel discussion on mRNA featuring Ziccum´s CEO - Force Family Office Fireside Chat

(36:43)